Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
4.420
-0.290 (-6.16%)
Jul 29, 2025, 4:00 PM - Market closed
Unicycive Therapeutics Employees
As of December 31, 2024, Unicycive Therapeutics had 23 total employees, including 22 full-time and 1 part-time employees. The number of employees increased by 9 or 64.29% compared to the previous year.
Employees
23
Change (1Y)
9
Growth (1Y)
64.29%
Revenue / Employee
n/a
Profits / Employee
-$701,870
Market Cap
55.87M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 23 | 9 | 64.29% |
Dec 31, 2023 | 14 | 2 | 16.67% |
Dec 31, 2022 | 12 | 3 | 33.33% |
Dec 31, 2021 | 9 | 8 | 800.00% |
Dec 31, 2020 | 1 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
UNCY News
- 5 days ago - Unicycive Therapeutics: Manageable CMC Speed-Bump--Pill-Burden Edge Intact, Buying - Seeking Alpha
- 5 days ago - Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology - GlobeNewsWire
- 10 days ago - UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm - Business Wire
- 21 days ago - Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 23 days ago - Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewsWire
- 4 weeks ago - Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - GlobeNewsWire
- 6 weeks ago - Unicycive Therapeutics, Inc. Announces Reverse Stock Split - GlobeNewsWire
- 7 weeks ago - Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - GlobeNewsWire